BioCentury
ARTICLE | Clinical News

Celgene won't seek Revlimid approval for DLBCL

July 25, 2016 7:00 AM UTC

Celgene Corp. (NASDAQ:CELG) said it does not plan to seek approval of Revlimid lenalidomide as a maintenance therapy for diffuse large B cell lymphoma patients who respond to first-line therapy of Rituxan rituximab plus CHOP chemotherapy. On Monday, the company said an interim analysis of overall survival data in the Phase III REMARC study showed Revlimid did not lead to an OS benefit vs. placebo in the indication.

Celgene said Revlimid met the primary endpoint of improving progression-free survival vs. placebo in REMARC, which enrolled 650 responders to induction therapy. ...